Phase III Soft Tissue Sarcoma Trials: Success or Failure?-Reference-Cited by-同舟云学术

Phase III Soft Tissue Sarcoma Trials: Success or Failure?

Published:2017-03 Issue:3 Volume:18 Page:
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Lee Alexander T. J.,Pollack Seth M.,Huang Paul,Jones Robin L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11864-017-0457-1.pdf

Reference54 articles.

1. PDQ Adult Treatment Editorial Board. Levels of evidence for adult and pediatric cancer treatment studies (PDQ®): health professional version [Internet]. PDQ Cancer Information Summaries. 2002 [cited 2016 Nov 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26389191 .

2. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4:103–12. doi: 10.1080/13577140020008066 .

3. •• Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23. doi: 10.1016/S1470-2045(14)70063-4 . Results of EORTC 62012 study, a large open-label phase III trial comparing single agent doxorubicin to combination doxorubicin-ifosfamide in untreated advanced STS.

4. • Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–97. doi: 10.1016/S0140-6736(16)30587-6 . Olarutumab, an anti-PDGFRa monoclonal antibody, has been granted FDA accelerated approval status on the basis of the overall survival benefit seen in this randomised phase II study in untreated advanced STS. A phase III trial of the same doxorubicin-olaratumab combination is now in follow-up.

5. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 2007;25(21):3144–50. doi: 10.1200/JCO.2006.09.7717 .

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer;Journal of Nanobiotechnology;2023-11-22

2. Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma;International Journal of Molecular Sciences;2022-07-06

3. Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment;Journal of Cancer Research and Clinical Oncology;2021-12-03

4. 18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition;Clinical Cancer Research;2021-10-06

5. Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model;Journal of Clinical Medicine;2021-05-25